Abate, T. 2001a. ‘Genentech can widen drug's use’, San Francisco Chronicle, 15 May, p. B1
Abate, T. 2001b. ‘Researchers ready to move to next genome discoveries; drug developers to see new tools at Trade Show’, San Francisco Chronicle, 5 March, p. C1
Abraham, J. 1995. Science, Politics and the Pharmaceutical Industry: Controversy and Bias in Drug Regulation. London: University College London/St Martins Press
Aerssens, J. 2002. ‘Pharmacogenomic approaches in Alzheimer's disease drug development’, Drug Development Research 56: 67–73
AGS Ethics Committee 2001. ‘Genetic testing for late-onset Alzheimer's disease’, Journal of the American Geriatric Society 49: 225–6
Akhtar, S. 2002. ‘Pharmacogenomics: are pharmacists ready for genotyped prescribing?’, Pharmaceutical Journal 268: 296–9
Almkvist, O, , Jelic, V., Amberla, K., Hellstrom-Lindhal, E., Meuling, L. and Nordberg, A. 2001. ‘Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients’, Dementia and Geriatric Cognitive Disorders 12(1): 22–32
Altman, L. K. 2000. ‘Reading the book of life: the doctor's world; genomic chief has high hopes, and great fears, for genetic testing’, New York Times, 27 June, section F, p. 6
Altman, R. 1996. Waking Up/Fighting Back: The Politics of Breast Cancer. Boston: Little, Brown
Álvarez, X. A., Mouzo, R., Pichel, V., Perez, P., Laredo, M., Fernandez-Novoa, L., Corzo, L., Zas, R., Alcaraz, M., Secades, J. J., Lozano, R. and Cacabelos, R. 1999. ‘Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion’, Methods and findings in Experimental and Clinical Pharmacology 21(9): 633–44
Anderson, D. C., Gomez-Mancilla, B., Spear, B. B., Barnes, D. M., Cheeseman, K., Shaw, P. M., Friedman, J., McCarthy, A., Brazell, C., Ray, S. C., McHale, D., Hashimoto, L., Sandbrink, R., Watson, M. L., Salerno, R. A., Cohen, N. and Lister, C. E. on behalf of the Pharmacogenetics Working Group 2002. ‘Elements of informed consent for pharmacogenetic research; perspective of the Pharmacogenetics Working Group’, Pharmacogenomics Journal 2(5): 284–92
Anderson, W. H., Fitzgerald, C. G. and Manasco, P. K. 1999. ‘Current and future applications of pharmacogenomics’, New Horizons: Science and Practice of Acute Medicine 7(2): 262–9
Anglin, M. K. 1997. ‘Working from the inside out: implications of breast cancer activism for biomedical policies and practices’, Social Science and Medicine 44(9): 1403–15
,Anon. 1998. ‘Editorial: pharmacogenomics at work’, Nature Biotechnology 16(10): 885
Anspach, R. 1993. Deciding who Lives: Fateful Choices in the Intensive-Care Nursery. Berkeley: University of California Press
Ashcroft, R. 1999. ‘Equipoise, knowledge and ethics in clinical research and practice’, Bioethics 13(3–4): 314–26
Ashmore, M., Mulkay, M. and Pinch, T. 1989. Health and Efficiency: A Sociology of Health Economics. Milton Keynes: Open University Press
Bailey, D. S., Bondar, A. and Furness, L. M. 1998. ‘Pharmacogenomics – it's not just pharmacogenetics’, Current Opinion in Biotechnology 9: 595–601
Barry, A. 2001. Political Machines: Governing a Technological Society. London and New York: Athlone
Barton, G. 2000. Genetic Services in the NHS: An Institute of Healthcare Management Discussion Paper. London: HMSO
Baselga, J. 2001. ‘Clinical trials of Herceptin® (trastuzumab)’, European Journal of Cancer 37: S18–S24
Bast, R. C., Ravdin, P., Hayes, D. F., Bates, S., Fritsche, H., Jessup, J. M., Kemeny, N., Locker, G. Y., Mennel, R. G. and Somerfield, M. R. 2001. ‘2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology’, Journal of Clinical Oncology 19(6): 1865–78
Batt, S. 1994. Patient no More: The Politics of Breast Cancer. London: Scarlet
Batt, S. 2000. ‘The new genetic therapies: the case of herceptin for breast cancer’, in The Gender of Genetic Futures: The Canadian Biotechnology Strategy. Women and Health Proceedings of the National Strategic Workshop, NNEWH Working Paper Series. Toronto: York University Press, pp. 9–17
Bazell, R. 1998. Her2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer. New York: Random House
Beauchamp, T. L. and Childress, J. F. 1993. Principles of Biomedical Ethics. 4th edn. Oxford: Oxford University Press
Bell, R. A., Wilkes, M. S. and Kravitz, R. L. 1999. ‘Advertisement-induced prescription drug requests: patient's anticipated reactions to a physician who refuses’, Journal of Family Practice 48(6): 446–52
Benbassat, J., Pilpel, D. and Tidhar, M. 1998. ‘Patient's preferences for participation in clinical decision making: a review of published surveys’, Behavioral Medicine 24(2): 81–8
Berg, J. W., Appelbaum, P. S., Lidz, C. W. and Parker, L. S. 2001. Informed Consent: Legal Theory and Clinical Practice. 2nd edn. Oxford: Oxford University Press
Bijker, W., Hughes, T. and Pinch, T. (eds.) 1987. The Social Construction of Technological Systems. Cambridge, MA: MIT Press
Bijker, W. E. and Law, J. (eds.) 1992. Shaping Technology-Building Society: Studies in Sociotechnical Change. Cambridge, MA: MIT Press
Binstock, R. H. and Murray, T. H. 1998. ‘Genetics and long-term-care insurance: ethical and policy issues’, in S. G. Post and P. J. Whitehouse (eds.), Genetic Testing for Alzheimer's Disease: Ethical and Clinical Issues. Baltimore: Johns Hopkins University Press, pp. 155–76
Birch, S. and Gafni, A. 2002. ‘On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales’, Health Economics 11: 185–91
Bird, T. 1995a. ‘Apolipoprotein E genotyping in diagnosis of Alzheimer's disease: a cautionary view’, Annals of Neurology 38(1): 2–3
Bird, T. 1995b. ‘Reply’, Annals of Neurology 38(6): 967
Birner, P. 2002. ‘Is fluorescence in situ hybridization really superior to Hercept Test?’ Journal of Clinical Oncology 20(23): 4607
Bogdanovic, S. and Langlands, B. 1999. Pharmacogenomics Players. London: Financial Times
Bonnor, J. 1998. ‘Designer drugs’, Guardian, 5 February, p. 14
Booth, B, ., Glassman, R. and Ma, P. 2003. ‘Oncology's trials’, Nature Reviews Drug Discovery 2(8): 609–10
Borroni, B., Colciaghi, F., Pastorino, L., Archetti, S., Corsini, P., Cattabeni, F., Di Luca, M. and Padovani, A. 2002. ‘ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model’, European Neuropsychopharmacology 12: 195–200
Boseley, S. 2003. ‘Cancer fund urged to end postcode lottery’, Guardian, 29 October, p. 11
Bosk, C. L. 1992. All God's Mistakes: Genetic Counselling in a Pediatric Hospital. Chicago: University of Chicago Press
Bosk, C. L. 2002. ‘Obtaining voluntary consent for research in desperately ill patients’, Medical Care 40(9): V64–8
Bowe, C. and Pilling, D. 2001. ‘Abbott labs links with Millennium’, Financial Times, 13 March, p. 17
Bracco, L. 2002. ‘Pharmacogenomics and personalised medicine’, Pharmacogenomics 3(2): 166–71
Branca, M. 2002. ‘Gambling on pharmacogenomics: a Q&A with Klaus Lindpaintner’, Bio IT World, 9 October, http://www_bio-itworld.com/archive/100902/path_sidebar_1303.htm
Brill-Edwards, M. 1999. ‘Canada's Health Protection Branch: whose health, what protection?’, in M. L. Barer, K. M. McGrail, K. Cardiff, L. Wood and C. J. Green (eds.), Tales from the Other Drug Wars: Papers from the 12th Annual Health Policy Conference (held in Vancouver, BC, 26 November 1999). Vancouver: University of British Columbia, Centre for Health Services and Policy Research, http://www.chspr.ubc.ca/misc/drugwars2.pdf
Brodaty, H., Conneally, M., Gauthier, S., Jennings, C., Lennox, A., Lovestone, S., Koczyn, A., Mangone, C., Rossor, M. and Whitehouse, P. 1995. ‘Consensus statement on predictive testing for Alzheimer Disease’, Alzheimer Disease and Associated Disorders 9(4): 182–7
Brower, V. 1997. ‘Allen Roses: rebel with a cause’, Nature Biotechnology 15: 1310
Brown, H. 2003. ‘Does hope match the hype for targeted drugs?’, Lancet Oncology 4(8): 452
Brown, L. 1998. ‘The evolution of managed care in the US’, Pharmacoeconomics 14(1): 37–43
Brown, N., Rappert, B. and Webster, A. (eds.) 2000. Contested Futures: A Sociology of Prospective Science and Technology. Aldershot: Ashgate
Bruera, E., Willey, J. S., Palmer, J. L. and Rosales, M. 2002. ‘Treatment decisions for breast carcinoma-patient preferences and physician perceptions’, Cancer 94(7): 2076–80
Buchanan, A., Califano, A., Kahn, J., McPherson, E., Robertson, J. and Brody, B. 2002. Pharmacogenetics: Ethical and Regulatory Issues in Research and Clinical Practice. Report of the Consortium on Pharmacogenetics. Findings and Recommendations. http://www.bioethics.umn.edu/News/pharm_report.pdf
Bullock, R. 2002. ‘New drugs for Alzheimer's disease and other dementias’, British Journal of Psychiatry 180: 135–9
Butler, R. N. 1994. ‘ApoE: new risk factor for Alzheimer's’, Geriatrics 49(8): 10–11
Cacabelos, R., Alvarez, A., Lombardi, A., Fernandez-Novoa, L., Corzo, L., Perez, P., Laredo, M., Pichel, V., Hernandez, A., Varela, M., Figueroa, J., Prous, J., Windisch, M. and Vigo, C. 2000. ‘Pharmacological treatment of Alzheimer's disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics’, Drugs of Today 36(7): 415–99
Cambrosio, A. and Keating, P. 1995. Exquisite Specificity. The Monoclonal Antibody Revolution. Oxford: Oxford University Press
Carlsson, M. 2000. ‘Cancer patients seeking information from sources outside the health care system’, Supportive Care in Cancer 8(6): 453–7
Casamayou, M. H. 2001. The Politics of Breast Cancer. Washington, DC: Georgetown University Press
Chadwick, R. 1999. ‘Criteria for genetic screening: the impact of pharmaceutical research’, Monash Bioethics Review 18(1): 22–6
Chamberlain, J. C. and Joubert, P. H. 2001. ‘Opportunities and strategies for introducing pharmacogenetics into early drug development’, Drug Discovery Today 6(11): 569–74
Chen, D. T., Miller, F. G. and Rosenstein, D. L. 2003. ‘Clinical research and the physician–patient relationship’, Annals of Internal Medicine 138(8): 669–72
Clarke, A., English, V., Harris, H. and Wells, F. 2001. ‘Report on ethical Considerations’, International Journal of Pharmaceutical Medicine 15: 89–94
Coats, A. 2000. ‘Pharmacogenomics: hope or hype?’, International Journal of Cardiology 76: 1–3
Cockett, M., Dracopoli, N. and Sigal, E. 2000. ‘Applied genomics: integration of the technology within pharmaceutical research and development’, Current Opinion in Biotechnology 11: 602–9
Collins, H. 1985. Changing Order: Replication and Induction in Scientific Practice. London: Sage
Collins, H. 1999. ‘Tantalus and the aliens: publications, audiences and the search for gravitational waves’, Social Studies of Science 29(2): 163–97
Connor, S. 1999. ‘Genetic blueprint to predict illness’, Independent, 15 April, p. 10
Connor, S. 2003a. ‘Glaxo chief: Our drugs do not work on most patients’. Independent, 8 December, p. 1
Connor, S. 2003b. ‘Demolished: the myth that allows drugs giants to sell more’. Independent, 8 December, p. 8
Cook-Deegan, R. 1998. ‘Some questions arising in the commercial development of genetic tests for Alzheimer's disease’, in S. Post and P. Whitehouse (eds.), Genetic Testing for Alzheimer Disease: Ethical and Clinical Issues. Baltimore: Johns Hopkins University Press, pp. 84–100
Cookson, C. 1999. ‘Future cancer research may emphasise control not cure’, Financial Times, 18 September, p. 7
Corrigan, O. 2002. ‘A risky business: the detection of adverse drug reactions in clinical trials and post-marketing exercises’, Social Science and Medicine 55(3): pp. 497–507
Cronin, M. T., Pho, M., Dutta, D., Frueh, F., Schwarcz, L. and Brennan, T. 2001. ‘Utilization of new technologies in drug trial and discovery’, Drug Metabolism and Disposition 29(4 part 2): 586–90
Cummings, J. L. 2003. ‘Use of cholinesterase inhibitors in clinical practice’, American Journal of Geriatric Psychiatry 11(2): 131–45
Cummins, F. 2002. ‘Breast cancer NHS pill’, Mirror, 16 March, p. 8
Cunning, A. M. and Robertson, F. W. 1984. ‘Polymorphism at the apolipoprotein E locus in relation to risk of coronary disease’, Clinical Genetics 25: 310–13
Czaban, J. N. 2001. ‘Pharmacogenomics: the uncertain path to decoding the regulatory genome’, Food and Drug Law Institute Update 3: 33
Day, M. 2002. ‘Women to win cancer drug fight’, Express, 15 March, p. 23
Department of Health 1999. ‘NICE proposals launched today: patients get faster access to modern treatment’, press release, 3 February
Department of Health 2003. Our Inheritance, Our Future. Realising the Potential of Genetics in the NHS. London: HMSO.
Department of Health 2003. The NHS Cancer Plan. Three Year Progress Report. Maintaining the Momentum. London: HMSO.
Diederich, F. 2002. ‘Nanotechnology – separating hype from reality’, Chemical Engineer Dec.: 26
DiMasi, J. A., Hansen, R. W., Grabowski, H. G. and Lasagna, L. 1991. ‘Cost of innovation in the pharmaceutical industry’, Journal of Health Economics 10: 107–42
DiMasi, J. A., Hansen, R. W. and Grabowski, H. G. 2003. ‘The price of innovation: new estimates of drug development costs’, Journal of Health Economics 22: 151–85
Drazen, J. M., Yandava, C. N., Dube, L.., Szczerback, N., Hippensteel, R., Pillari, A., Israel, E., Schork, N, Silverman, E. S., Katz, D. A. and Drajesk, J. 1999. ‘Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment’, Nature Genetics 22: 168–70
Economist, 1997. ‘Drug companies’ target practice', Economist, 6 December, pp. 94–5
Einsiedel, E. F. and Eastlick, D. L. 2000. ‘Consensus conferences as deliberative democracy – a communications perspective’, Science Communication 21(4): 323–43
Elder, A. T. and Fox, K. A. A. 1992. ‘Thrombolytic treatment for elderly patients’, British Medical Journal 305: 846–7
Ellis, I. O., Dowsett, M., Bartlett, J., Walker, R., Cooke, T., Gullick, W., Gusterson, B., Mallon, E. and Barrett Lee, P. 2000. ‘Recommendations for HER2 testing in the UK’, Journal of Clinical Pathology 53: 890–2
EMEA 2000. Report to the CPMP on the EMEA Seminar on the use of Pharmacogenetics in the Drug Development Process. 5 June. London: EMEA
Emery, J. and Hayflick, S. 2001. ‘The challenge of integrating genetic medicine into primary care’, British Medical Journal 322: 1027–30
Emilien, G., Ponchon, M., Caldas, C., Isacson, O. and Maloteaux, J. M. 2000. ‘Impact of genomics on drug discovery and clinical medicine’, Quarterly Journal of Medicine 93(7): 391–423
Ensom, M. H. H., Chang, T. H. K. and Patel, P. 2001. ‘Pharmacogenetics: the therapeutic drug monitoring of the future’, Clinical Pharmacokinetics 40(11): 783–802
Epstein, S. 1996. Impure Science: AIDS, Activism and the Politics of Knowledge. Berkeley: University of California Press
Evans, W. E. and Relling, M. 1999. ‘Pharmacogenomics: translating functional genomics into rational therapeutics’, Science 286: 487–91
Evans, W. E. and Johnson, J. A. 2001. ‘Pharmacogenomics: the inherited basis for interindividual differences in drug response’, Annual Review of Genomics and Human Genetics 2: 9–39
Evans, W. E. and McLeod, H. L. 2003. ‘Pharmacogenomics – drug disposition, drug targets and side effects’, New England Journal of Medicine 348(6): 538–49
Farlow, M., Gracon, S., Hershey, L., Lewis, K., Sadowsky, C. and Dolanureno, J. 1992. ‘A controlled trial of Tacrine in Alzheimer's disease’, Journal of the American Medical Association 268( 18): 2523–9
Farlow, M., Lahiri, D. K., Poirier, J., Davignon, J. and Hui, S. 1996. ‘Apolipoprotein E genotype and gender influence response to tacrine therapy’, Annals of the New York Academy of Science 802: 101–10
Farlow, M., Lahiri, D. K., Poirier, J.., Davignon, J., Schneider, L. and Hui, S. L. 1998. ‘Treatment outcome of tacrine therapy depends on apolipoprotein E genotype and gender of the subject with Alzheimer's disease’, Neurology 50: 669–77
Farrer, L. A., Brin, M. F., Elsas, L., Goate, A., Kennedy, J., Mayeux, R., Myers, R. H., Reilly, P. and Risch, N. J. 1995. ‘Statement on use of apolipoprotein-E testing for Alzheimer-disease’, Journal of the American Medical Association 274 (20): 1627–9
FDA 1991. ‘Tacrine as a treatment for Alzheimer's dementia: an interim report from the FDA’, New England Journal of Medicine 324(5): 349–52
Feldman, A. M., Lorell, B. H. and Reis, S. E. 2000. ‘Trastuzumab in the treatment of metastatic breast cancer’, Circulation 102: 272–4
Feltham, C. 2002. ‘Pioneer's bright vision for new age of medicine’, Daily Mail, 10 October, p. 81
Fentiman, I. S. 1998. Detection and Treatment of Breast Cancer. 1st edn. London: Martin Dunitz
Ferentz, A. E. 2002. ‘Integrating pharmacogenomics into drug development’, Pharmacogenomics 3(4): 453–67
Ferguson, J. H. 1996. ‘The NIH consensus development program: the evolution of guidelines’, International Journal of Technology Assessment in Health Care 12(3): 460–74
Financial Times (FT) 1994. ‘Alzheimer's drug hope for sufferers’, Financial Times, 6 April, p. 9
Financial Times (FT) 1997. ‘FT guide to: Genetic engineering’, Financial Times, 29 September, p. 10
Financial Times (FT) 2001. ‘Inside track’, Financial Times, 12 July, p. 10
Firn, D. 2000. ‘EU gives approval for Roche cancer treatment’, Financial Times, 31 August, p. 31
Fogarty, M. 1998. ‘Up for adoption: pharmacogenetics and the orphan drug law’, HMS Beagle 44, http://news.bmn.com/hmsbeagle/44/people/op_ed.htm
Fortun, M. 1998. ‘Sixty-five roses, Pulmozyme. Steve Shak, Genentech Inc.’, in G. E. Marcus, (ed.), Late Edition 5: Corporate Futures. Chicago: University of Chicago Press, pp. 209–42
Fortun, M. 2001. ‘Mediated speculations in the genomics futures markets’, New Genetics and Society 20(2): 139–56
Fox, R. C. and Swazey, J. P. 1984. ‘Medical morality is not bioethics – medical ethics in China and the United States’, Perspective in Biology and Medicine 27(3): 336–60
Frank, R. G. 2003. ‘Editorial: New estimates of drug development costs’, Journal of Health Economics 22: 325–30
Franz, S. and Smith, A. 2003. ‘New drug approvals for 2002’, Nature Reviews Drug Discovery 2: 95–6
Freedman, B. 1987. ‘Equipoise and the ethics of clinical research’, New England Journal of Medicine 317(3): 141–5
Freeman, C. and Soefe, L. 1997. The Economics of Industrial Innovation. 3rd edn. London: Cassell
Frisoni, G. B. 2001. ‘Treatment of Alzheimer's disease with acetylcholinesterase inhibitors: bridging the gap between evidence and practice’, Journal of Neurology 248: 551–7
Frith, M. 2003. ‘Reid orders inquiry into postcode drug prescribing’, Independent, 29 October, p. 6
Frost, S., Myers, L. B. and Newman, S. P. 2001. ‘Genetic screening for Alzheimer's disease: what factors predict intentions to take a test?’, Behavioral Medicine 27(3): 101–9
GeneWatch, 2003. Pharmacogenetics: Better, Safer Medicines? Briefing number 23
GenomeWeb 2001. ‘Pharmacogenomics seen growing to $6B by 2005, report says’, http://www.genomeweb.com/articles/view.asp? Article no. 20017355957
Ginsburg, G. and McCarthy, J. 2001. ‘Personalized medicine: revolutionizing drug discovery and patient care’, Trends in Biotechnology 19(12): 491–9
Glaser, V. 1998. ‘Pharmacogenomics: laying the foundation for prescriptive medicine’, Genetic Engineering News, 1 January, pp. 1, 9, 31 and 39
Gonzalez, F. J., Skoda, R. C., Kimura, S., Umeno, M., Zanger, U. M., Nebert, D. W., Gelboin, H. Y., Hardwick, J. P. and Meyer, U. A. 1988. ‘Characterization of the common genetic-defect in humans deficient in debrisoquine metabolism’, Nature 331(6155): 442–6
Goodman, J. and Walsh, V. 2001. The Story of Taxol: Nature and Politics in the Pursuit of an Anti-Cancer Drug. Cambridge: Cambridge University Press
Gottlieb, S. 2000. ‘Cancer drug may cause heart failure’, British Medical Journal 321: 259
Graydon, J., Galloway, S., Palmer, Wickham S., Harrison, D., Richvanbder Bij, L., West, P., Burlein Hall, S. and Evans, Boyden B. 1997. ‘Information needs of women during early treatment for breast cancer’, Journal of Advanced Nursing 26(1): 59–64
Green, M. C., Murray, J. L. and Hortobagyi, G. N. 2000. ‘Monoclonal antibody therapy for solid tumors’, Cancer Treatment Reviews 26: 269–86
Griffith, V. 2000. ‘Mammoth task to untangle the genome: interpreting the genome’, Financial Times, 15 November, Biotechnology supplement, p. 2
Griffith, V. 2001. ‘Tailored care for cancer patients genetics’, Financial Times, 3 May, p. 10
Griffith, V. 2003a. ‘Breakthrough in tailor-made medicines. ASCO Conference’, Financial Times, 2 June, p. 26
Griffith, V. 2003b. ‘Optimistic Genentech reports earnings increase’, Financial Times, 16 January, p. 18
Growden, J. H. 1998. ‘Editorial: Apolipoprotein E and Alzheimer disease’, Archives of Neurology 55: 1053–4
Guardian, , 2003. ‘Roche's biggest sellers’, Guardian, 27 February, p. 28
Guice, J. 1999. ‘Designing the future: the culture of new trends in science and technology’, Research Policy 28: 81–98
Guston, D. H. 1999. ‘Evaluating the first US consensus conference: the impact of the citizens’ panel on telecommunications and the future of democracy', Science, Technology and Human Values 24(4): 451–82
Hack, T. F., Degner, L. F. and Dyck, D. G. 1994. ‘Relationship between preferences for decisional control and illness information among women with breast cancer’, Social Science and Medicine 39: 279–89
Hall, C. 1995. ‘Makers appeal for Alzheimer's drug licence’, Independent, 22 March, p. 4
Hamilton, A. and Piccart, M. 2000. ‘The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2’, Annals of Oncology 11: 647–63
Harrison, S. 1998. ‘The politics of evidence-based medicine in the United Kingdom’, Policy and Politics 26(1): 15–31
Haseltine, W. 1998. ‘Letter: Not quite pharmacogenomics’, Nature Biotechnology 16(12): 1295
Hawkes, N. 2002. ‘£15,500 breast cancer drug to be free on NHS’ The Times, 16 March, p. 6
Hedgecoe, A. 2003. ‘Terminology and the construction of scientific disciplines: the case of pharmacogenomics’, Science, Technology and Human Values 28(4): 513–37
Hedgecoe, A. and Martin, P. 2003. ‘The drugs don't work: expectations and the shaping of pharmacogenetics’, Social Studies of Science 33(3): 327–64
Herrman, N., Sadavoy, J. and Steingart, A. 1987. ‘Letter’, New England Journal of Medicine 316(25) 1603–4
Highfield, R. 2001. ‘Genetic scientists in commercial row over “Book of Life”’, Daily Telegraph, 13 February, p. 14
Highfield, R. 2002. ‘500,000 to provide DNA samples for “biobank”’, Daily Telegraph, 29 April, p. 6
Hoban, C. J. 2002. ‘From the lab to the clinic: integration of pharmacogenetics into clinical practice’, Pharmacogenomics 3(4): 429–36
Hortobagyi, G. N. and Perez, E. A. 2001. ‘Integration of Trastuzumab into adjuvant systemic therapy of breast cancer: ongoing and planned clinical trials’, Seminars in Oncology 28(5), supplement 16: 41–6
Houghton, J. and Tobias, J. S. 2001. ‘Adjuvant radiotherapy in the management of early breast cancer’, in J. S. Tobias, J. Houghton and I. C. Henderson (eds.), Breast Cancer: New Horizons in Research and Treatment. London: Edward Arnold. pp. 189–94
Housman, D. and Ledley, F. 1998. ‘Why pharmacogenomics? Why now?’, Nature Biotechnology 16: 492–3
Hughes, D. and Griffiths, L. 1997. ‘“Ruling in” and “ruling out”: two approaches to the micro-rationing of health care’, Social Science and Medicine 44(5): 589–99
Hughes, T. P. 1983. Networks of Power: Electrification in Western Society 1880–1930. Baltimore: Johns Hopkins University Press
Hunt, L. 1996. ‘Unravelling the tangles of dementia’, Independent on Sunday, 28 April, Sunday Review, p. 42
Hurst, J. 1998. ‘The impact of health economics on health policy in England, and the impact of health policy on health economics 1972–1977’, Health Economics 7: S47–S62
Hutton, J. and Maynard, A. 2000. ‘A NICE challenge for health economics’, Health Economics 9: 89–93
Hyman, B. T. and Wallace, R. B. 1997. ‘Reply’, Annals of Neurology 41(3): 415–16
Independent 2000. ‘Genome challenge’, Independent, 28 June, p. 20
Independent 2003. ‘Leader: Multinational drug company: honest, decent, public-spirited?’, Independent, 8 December, p. 16
Ingelman-Sundberg, M. 2001. ‘Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy’, Journal of Internal Medicine 250: 186–200
Irwin, A. and Wynne, B. 1996. Misunderstanding Science? The Public Reconstruction of Science and Technology. Cambridge: Cambridge University Press
Issa, A. M. 2000. ‘Ethical considerations in clinical pharmacogenomics research’, Trends in Pharmacological Science 21: 247–9
Issa, A. M. 2002. ‘Ethical perspectives on pharmacogenomic profiling in the drug development process’, Nature Reviews Drug Discovery 1(4): 300–8
Issa, A. M. and Kegserlingk, E. W. 2000. ‘Apolipoprotein E genotyping for pharmacogenetic purposes in Alzheimer's disease: emerging ethical issues’, Canadian Journal of Psychiatry 45: 917–2
Jacoby, I. 1985. ‘Editorial: The consensus development program of the National Instititues of Health’, American Journal of Psychiatry 142(4): 477–8
James, R. J. 2002. ‘Commentary on Kewell et al. (2002), Calman-Hine reassessed’, Journal of Evaluation in Clinical Practice 8(3): 299–301
Jazwinska, E. C. 2001. ‘Exploiting human genetic variation in drug discovery and development’, Drug Discovery Today 6(4): 198–205
Jenkins, P. 2002. ‘The future is made-to-measure: pharmacogenomics’, Financial Times, 30 April, Survey section, p. 3
Johnson, J. A. and Evans, W. E. 2002. ‘Molecular diagnostics as a predictive tool: genetics of drug efficacy and toxicity’, Trends in Molecular Medicine 8(6): 300–5
Johnston, L. 2001. ‘Scandal of the vital life-saving treatments that NHS won't buy’, Sunday Express, 29 July, p. 11
Jordan, K. and Lynch, M. 1998. ‘The dissemination, standardization and routinization of a molecular biological technique’, Social Studies of Science 28(5–6): 733–800
Jordan, V. C. 2003. ‘Tamoxifen: a most unlikely pioneering medicine’, Nature Reviews Drug Discovery 2: 205–13
Joss, S. and Bellucci, S. (eds.) 2002. Participatory Technology Assessment. European Perspectives. London: CSD and TA Swiss
Kakulas, B. A. and Bockxmeer, F. M. 1995. ‘Apolipoprotein E genotyping in the diagnosis of Alzheimer's disease: a cautionary view’, Annals of Neurology 38(6): 966–7
Kalow, W. 1990. ‘Pharmacogenetics: past and future’, Life Sciences 47: 1385–97
Kandohla, T. 2002. ‘Deadly delay’, Sun, 16 March, p. 29
Kaptain, S., Tan, L. K. and Chen, B. 2001. ‘Her-2/ neu and breast cancer’, Diagnostic Molecular Pathology 10(3): 139–52
Kendall, P. 2001. ‘Tailor-made drugs to combat cancer’, Daily Mail, 22 February, p. 39
Kewell, B., Hawkins, C. and Ferlie, E. 2002. ‘Calman–Hine reassessed: a survey of cancer network development in England, 1999–2000’, Journal of Evaluation in Clinical Practice 8(3): 303–11
Klawiter, M. 2000. ‘Racing for the cure, walking women and toxic touring: mapping cultures of action within the Bay area terrain of breast cancer’, in Potts L. K. (ed.) Ideologies of Breast Cancer: Feminist Perspectives. London: Macmillan, pp. 63–97
Klein, R. 2001. The New Politics of the National Health Service. 4th edn. London: Prentice Hall
Klein, R., Day, P. and Redmayne, S. 1996. Managing Scarcity: Priority Setting and Rationing in the National Health Service. Milton Keynes: Open University Press
Kleyn, P. W. and Vesell, E. S. 1998. ‘Genetic variation as a guide to drug development’, Science 281: 1820–1
Knopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey-Bloom, J., Relkin, N., Small, G. W., Miller, B. and Stevens, J. C. 2001. ‘Practitioner parameter: diagnosis of dementia (an evidence based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology’, Neurology 56: 1143–53
Koenig, P. 1991. ‘Money and the medicine men’, Independent on Sunday, 12 May, Review section, p. 2
Koepp, R. and Miles, S. H. 1999. ‘Meta-analysis of Tacrine for Alzheimer disease: the influence of industry sponsors’, Journal of the American Medical Association 281(24) (June 23/30): 2287
Kolata, G. 1999. ‘Using gene tests to customize medical treatment’, New York Times, 20 December, Section A, p. 1
Koselleck, R. 1985. Futures Past: On the Semantics of Historical Time. Cambridge, MA: MIT Press
Krall, W. J., Sramek, J. J. and Cutler, N. R. 1999. ‘Cholinesterase inhibitors: a therapeutic strategy for Alzheimer's disease’, Annals of Pharmacology 33: 441–50
Kuczewski, M. G. and Marshall, P. 2002. ‘The decision dynamics of clinical research: the context and process of informed consent’, Medical Care 40(9) special supplement: 45–54
Kuivenhoven, J., Jukema, W., Zwinderman, A., Knijff, P., McPherson, R., Bruschke, A., Lie, K. and Kastelein, J. 1998. ‘The role of a common variant of the CETP gene in the progression of coronary artherosclerosis’, New England Journal of Medicine 338(2): 86–93
Kumar, S. 1999. ‘Resisting revolution: generalism and the new genetics’, Lancet 354: 1992–3
Kumar, S. and Gantley, M. 1999. ‘Tensions between policy makers and general practitioners in implementing new genetics: grounded theory interview study’, British Medical Journal 319: 1410–13
Kurth, J. H. 2000. ‘Pharmacogenomics: future promise of a tool for identifying patients at risk’, Drug Information Journal 34: 223–7
Lahiri, D. K., Farlow, M., Greig, N. H. and Sambamurti, K. 2002. ‘Current drug targets for Alzheimer's disease treatment’, Drug Development Research 56: 267–81
Lanctôt, K. L., Hermann, N. and LouLou, M. M. 2003. ‘Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease’, Journal of Psychiatry and Neuroscience 28(1): 13–26
Lappin, T. 2001. ‘The year in ideas: A to Z – Pharmacogenomics’, New York Times, 9 December, section 6, p. 88
Larkin, M. 1997. ‘Allen Roses: “Enfant terrible” of Alzheimer's research’, Lancet 349: 1302
Latour, B. 1987. Science in Action: How to Follow Scientists and Engineers Through Society. Cambridge, MA: Harvard University Press
Latour, B. 1988. The Pasteurization of France. Cambridge, MA: Harvard University Press
Lau, K. and Sakul, H. 2000. ‘Pharmacogenomics’, in A. M. Doherty (ed.), Annual Reports in Medicinal Chemistry. London and San Diego: Academic Press, pp. 261–9
Laurance, J. 2002. ‘£20,000-a-year cancer drug approved for NHS’, Independent, 16 March, p. 4
Lavori, P. W., Krause-Steinrauf, H., Brophy, M., Buxbaum, J., Cockroft, J., Cox, D. R., Fiore, L., Greely, H. T., Greenberg, H., Holmes, E. W., Nelson, L. M. and Sugarman, J. 2002. ‘Principles, organization, and operation of a DNA bank for clinical trials: a Department of Veterans Affairs cooperative study’, Controlled Clinical Trials 23(3): 222–39
Law, J. 1987. ‘Technology and heterogeneous engineering: the case of Portuguese expansion’, in W. Bijker, T. Hughes and T. J. Pinch (eds.), The Social Construction of Technological Systems: New Directions in the Sociology and History of Technology. Cambridge, MA.: MIT Press, pp. 111–3
Lazarou, J., Pomeranz, B. H. and Corey, P. N. 1998. ‘Incidence of adverse drug reactions in hospitalized patients’, Journal of the American Medical Association 279(15): 1200–5
Lebeau, A., Deimling, D., Kaltz, C., Sendelhofert, A., Iff, A., Luthardt, B., Untch, M. and Lohrs, U. 2001. ‘HER-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization’, Journal of Clinical Oncology 19(2): 354–63
Lehman Brothers. 2001. The Fruits of Genomics. New York: Lehman Brothers
Lerner, B. H. 2001. The Breast Cancer Wars: Hope, Fear and the Pursuit of a Cure in Twentieth-Century America. Oxford: Oxford University Press
Leyland-Jones, B. 2002. ‘Trastuzumab: hopes and realities’, Lancet Oncology 3: 137–44
Liggett, S. B. 2001. ‘Pharmacogenetic applications of the Human Genome Project’, Nature Medicine 7(3): 281–3
Lindpaintner, K. 1999. ‘Genetics in drug discovery and development: challenge and promise of individualizing treatment in common complex disease’, British Medical Bulletin 55(2): 471–91
Lindpaintner, K. 2002. ‘The importance of being modest – reflections on the pharmacogenetics of abacavir’, Pharmacogenomics 3(6): 835–8
Lindpaintner, K. 2003. ‘Pharmacogenetics: a new – or not so new? – concept in healthcare’, Geneva Papers on Risk and Insurance 28(2): 316–30
Lindpaintner, K., Foot, E., Caulfield, M. and Hall, I. 2001. ‘Pharmacogenetics: focus on pharmacodynamics’, International Journal of Pharmaceutical Medicine 15: 74–82
Lipman, T. 2001. ‘Letter: NICE and evidence based medicine are not really compatible’, British Medical Journal 322: 489–90
Lipton, P. 2003. ‘Pharmacogenetics: the ethical issues’, Pharmacogenomics Journal 3: 14–16
Littlejohns, P., Barnett, D. and Longson, C. 2003. ‘The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence’, Lancet Oncology 4: 242–50
Lohrisch, C. and Piccart, M. 2001. ‘An overview of HER2’, Seminars in Oncology 28(6): 3–11
Lovestone, S. 1998. ‘Letter: Genetics consortium can offer views facilitating best practice in Alzheimer's disease’, British Medical Journal 317: 471
Lovestone, S., Wilcock, G., Rosser, M., Cayton, H. and Ragan, I. 1996. ‘Letter: apolipoprotein E genotyping in Alzheimer's disease’, Lancet 347: 1775–6
Lucotte, G., Oddoze, C. and Michel, B. F. 1995. ‘Apolipoprotein E and response to tacrine in French Alzheimer's disease patients’, abstract presented at the International Psychogeriatrics Association Conference, Apolipoprotein E et Maladie d'Alzheimer, 29 May, Paris
MacGowan, S. H., Scott, M., Agg, M. and Wilcock, G. 1995. ‘Influence of apolipoprotien E genotype on response to tacrine in male and female patients with Alzheimer's disease’, abstract presented at the International Psychogeriatrics Association Conference, Apoilpoprotien E et Maladie d'Alzheimer, 29 May, Paris
Macgowan, S. H., Wilcock, G. and Scott, M. 1998. ‘Effect of gender and apolopoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease’, International Journal of Geriatric Psychiatry 13: 625–30
MacKenzie, D. 1990. Inventing Accuracy: A Historical Sociology of Nuclear Missile Guidance. Cambridge, MA: MIT Press
MacKenzie, D. 1998. ‘The certainty trough’, in R. Williams, W. Faulkner and J. Fleck (eds.), Exploring Expertise: Issues and Perspectives. London: Macmillan, pp. 325–9
MacKenzie, D. and Wajcman, J. (eds.) 1999. The Social Shaping of Technology. 2nd edn. Milton Keynes: Open University Press
Macklin, R. 1999. Against Relativism: Cultural Diversity and the Search for Ethical Universals in Medicine. Oxford: Oxford University Press
Maimone, D., Dominici, R. and Grimaldi, L. 2001. ‘Pharmacogenomics of neurodegenerative diseases’, European Journal of Pharmacology 413: 11–29
Maitland-van der Zee, A. H., Boer, A. and Leufkens, H. G. M. 2000. ‘The interface between pharmacoepidemiology and pharmacogenetics’, European Journal of Pharmacology 410: 121–30
Mancinelli, L., Cronin, M. and Sadée, W. 2000. ‘Pharmacogenomics: the promise of personalized medicine’, AAPS Pharmsci 2(1) (7 March): article 4
March, R. 2000. ‘Pharmacogenomics: the genomics of drug response’, Yeast 17: 16–21
March, R., Cheeseman, K. and Doherty, M. 2001. ‘Pharmacogenetics – legal, ethical and regulatory considerations’, Pharmacogenomics 2(4): 317–27
Margolese, R. G. 2001. ‘Neoadjuvant systemic primary therapy – is surgery the true adjuvant?’, in J. S. Tobias, J. Houghton and I. C. Henderson (eds.), Breast Cancer: New Horizons in Research and Treatment. London: Edward Arnold, pp. 177–87
Marsh, B. 2001. ‘Breast cancer victim uses mother's £20,000 savings as NHS refuses to buy drug; how cruel postcode lottery denies a wife her “last chance” of survival’, Daily Mail, 27 December, p. 17
Marsh, B. 2003. ‘Thousands still dying in cancer postcode lottery’, Daily Mail, 29 October, p. 10
Marshall, A. 1997. ‘Getting the right drug into the right patient’, Nature Biotechnology 15: 1249–52
Marshall, A. 1998. ‘Laying the foundations for personalized medicines’, Nature Biotechnology 16, supplement: 6–8
Marshall, E. 1998. ‘Allen Roses: from “street-fighter” to corporate insider’, Science 280: 1001–4
Martin, P. 1995. ‘The American gene therapy industry and the social shaping of a new technology’, Genetic Engineer and Biotechnologist 15(2–3): 155–67
Martin, P. 1999. ‘Genes as drugs: the social shaping of gene therapy and the reconstruction of genetic disease’, Sociology of Health and Illness 21: 517–38
Maroc, J. 1993. ‘New Alzheimer's theory stirs controversy’, Science 262: 1210–11
Maslin, A. M. and Powles, T. 1999. Breast Cancer: Sharing the Decision. Oxford: Oxford University Press
Mayeux, R., Saunders, A. M., Shea, S., Mirra, S., Evans, D., Roses, A. D., Hyman, B. T., Crain, B., Tang, M. X. and Phelps, C. H. 1998. ‘Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease’, New England Journal of Medicine 338(8): 506–11
McConnell, L. M., Koenig, B. A., Greely, H. T. and Raffin, T. A. 1998. ‘Genetic testing and alzheimer's disease: has the time come?’, Nature Medicine 4: 757–9
McConnell, L. M., Sanders, G. D. and Owens, D. K. 1999. ‘Evaluation of genetic tests: APOE genotyping for the diagnosis of Alzheimer disease’ Genetic Testing 3(1): 47–53
McKie, R. 1999. ‘Genetic key to personal medicines’, Observer, 5 December, p. 9
McLeod, H. L. and Evans, W. E. 2001. ‘Pharmacogenomics: unlocking the human genome for better drug therapy’, Annual Review of Pharmacology and Toxicology 41: 101–21
McNeil, C. 1998. ‘Herceptin raises its sights beyond advanced breast cancer’, Journal of the National Cancer Institute 90(12): 882–3
Medical Research Council 2003. ‘MRC response to the MHRA consultation letter on the Medicines for Human Use (Clinical Trials) Regulations 2003 (MLX 287) and draft legislation’. London: Medical Research Council
Merz, J. F., Cho, M. K. and Leonard, D. G. B. 1998. ‘Letter: testing for Alzheimer's’, Science 281: 1288–9
Meyer, U. A. 1990. ‘Molecular genetics and the future of pharmacogenetics’, Pharmacological Therapies 46: 349–55
Meyer, U. A. 2000 ‘Pharmacogenetics and adverse drug reactions’, Lancet 356: 1667–71
Miles, D. W. 2001. ‘Update on HER-2 as a target for cancer therapy: herceptin in the clinical setting’, Breast Cancer Research 3: 380–4
Miller, S. and Gregory, J. 1998. Science in Public: Communication, Culture and Credibility. New York: Plenum
Mitchell, M. S. and Press, M. F. 1999. ‘The role of immunohistochemistry and fluorescence in situ hybridization for HER-2/neu in assessing the prognosis of breast cancer’, Seminars in Oncology 26(4), supplement 12: 108–16
Mokbel, K. and Hassanally, D. 2001. ‘From HER2 to herceptin’, Current Medical Research and Opinions 17(1): 51–9
Møldrup, C. 2001. ‘Ethical, social and legal implications of pharmacogenomics: a critical review’, Community Genetics 4: 204–14
Moore, W. 2001. ‘Designer drugs: in less than a decade, tailor-made medication could make fatal side effects a thing of the past’, Observer, 15 April, p. 47
Moyses, C. 1999. ‘Pharmacogenetics, genomics, proteomics: the new frontiers in drug development’, International Journal of Pharmaceutical Medicine 13(4): 197–202
Mudher, A. and Lovestone, S. 2002. ‘Alzheimer's disease – do Tauists and Baptists finally shake hands?’, Trends in Neuroscience 25(1): 22–6
Mullan, F. and Jacoby, I. 1985. ‘The town meeting for technology: the maturation of consensus conferences’, Journal of the American Medical Association 254(8): 1068–72
Murphy, M. P. 2000. ‘Pharmacogenomics: a new paradigm for drug development’, Drug Discovery World (fall): 1–7
Murray, M. D. and Deardorff, F. W. 1998. ‘Does managed care fuel pharmaceutical industry growth?’, Pharmacoeconomics 14(4): 341–8
Myers, G. 1990a. Writing Biology: Texts in the Social Construction of Scientific Knowledge. Madison, WI: University of Wisconsin Press
Myers, G. 1990b. ‘Making a discovery: narratives of split genes’, in C. Nash (ed.), Narrative in Culture. The Uses of Storytelling in the Sciences, Philosophy, and Literature. London: Routledge, pp. 102–25
Myers, G. 1991. ‘Stories and styles in two molecular biology review articles’, in C. Bazerman and J. Paradis (eds.), Textual Dynamics of the Professions. Madison, WI: University of Wisconsin Press, pp. 45–75
National Institute for Clinical Excellence 2001. ‘NICE issues guidance on drugs for Alzheimer's disease’, press release, 19 January
National Institute for Clinical Excellence 2002. Guidance on the Use of Trastuzumab for the Treatment of Advanced Breast Cancer. London: National Institute for Clinical Excellence
Nebert, D. W. 1997. ‘Pharmacogenetics: 65 candles on the cake’, Pharmacogenetics 7: 435–40
Neumann, P. J., Hammitt, J. K., Mueller, C., Fillit, H. M., Hill, J., Tetteh, N. A. and Kosik, K. S. 2001. ‘Public attitudes about genetic testing for Alzheimer's disease’, Health Affairs 20(5): 252–64
Newdick, C. 1995. Who Should We Treat?: Law, Patients and Resources in the NHS. Oxford: Clarendon
Nicoletto, M. O., Donach, M., Nicolo, A., Artioli, G., Banna, G. and Monfardini, S. 2001. ‘BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling’, Cancer Treatment Reviews 27: 295–304
Norton, R. M. 2001. ‘Clinical pharmacogenomics: applications in pharmaceutical R&D’, Drug Discovery Today 6(4): 180–5
Nuffield Council on Bioethics 2003. Pharmacogenetics. Ethical Issues: Report of Working Party. London: Nuffield Council on Bioethics
O'Connell, S. 2001. ‘Could medicines be made to measure?’, Independent, 31 August, p. 8
Oddoze, C., Michel, B. F., Berthezene, P., Clavel, C. and Lucotte, G. 1998. ‘Apolipoprotein E epsilon 4 allele predicts a positive response to tacrine in Alzheimer's disease’, Alzheimer's Report 1(1): 13–16
Oddoze, C., Michel, B. F. and Lucotte, G. 2000. ‘Apolipoprotein E epsilon 4 allele predicts a better response to donepezil therapy in Alzheimer's disease’, Alzheimer's Report 3(4): 213–16
Oestreicher, P. 2001. ‘4th Annual Pharmacogenomics and Medicine Lecture: 3 April 2001, New Haven, Connecticut’, Pharmacogenomics 2(3): 291–6
Olson, J. S. 2002. Bathsheba's Breast: Women, Cancer and History. Baltimore: Johns Hopkins University Press
Pang, T. and Weatherall, D. 2002. ‘Genomics and global health: hype, reality, and a call for action in the developing and the developed world’, British Medical Journal 324: 1051–2
Pauletti, G., Dandekar, S., Rong, H. M., Ramos, L., Pong, H. J., Seshadri, R. and Slamon, D. J. 2000. ‘Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry’, Journal of Clinical Oncology 18(21): 3651–64
Paul, J. E. and Trueman, P. 2001. ‘Fourth hurdle reviews, NICE, and database applications’, Pharmacoepidemiology and Drug Safety 10: 429–38
Paulson, H. L. 2002. ‘Diagnostic testing in neurogenetics. Principles, limitations, and ethical considerations’, Neurologic Clinics of North America 20: 627–43
Perez, E. A. and Hortobagyi, G. N. 2000. ‘Ongoing and planned adjuvant trials with trastuzumab’, Seminars in Oncology 27(6), Supplement 11: 26–32
Perlman, D. 1999. ‘Stubborn scientists, heroic women lead to a cancer breakthrough’, San Francisco Chronicle, 17 January, Sunday Review, p. 5
Perry, S. 1987. ‘The NIH Consensus development program: a decade later’, New England Journal of Medicine 317(8): 485–8
Persing, B. F. and Cheek, D. J. 2000. ‘Pharmacogenomics’, Nursing Clinics of North America 35(4): 975–80
Pfost, D. R., Boyce-Jacino, M. T. and Grant, D. M. 2000. ‘A SNPshot: pharmacogenetics and the future of drug therapy’, Trends in Biotechnology 18: 334–8
Pharma, Marketletter, 1993. ‘HMO excludes Cognex from formulary’, Pharma Marketletter, 4 October
Pharma, Marketletter, 1999. ‘SB licences Memris to UK biotech Cerebrus’, Pharma Marketletter, 1 June
Pharmaceutical Business News 1994. ‘Athena Neurosciences to acquire Genica Pharmaceuticals’, Pharmaceutical Business News, 21 December
Phillips, K., Veenstra, D., Oren, E., Lee, L. and Sadée, W. 2001. ‘Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review’, Journal of the American Medical Association, 286(18): 2270–9
Piccart, M. and Kaufman, M. 2001. ‘Introduction’, European Journal of Cancer 37: S1–S2
Pilling, D. 1999a. ‘Drug group in drive for cancer breakthrough’, Financial Times, 11 November, p. 14
Pilling, D. 1999b. ‘Smarter weapons to combat cancer’, Financial Times, 12 November, Comment and Analysis section, p. 21
Pilling, D. 2000. ‘Uncertainty prefaces book of life’, Financial Times, 18 December, Weekend section, p. 1
Pinch, (T. J. and Bijker, (W. E. 1987. ‘The social construction of facts and artefacts – or how the sociology of science and the sociology of technology might benefit each other’, in Bijker, Hughes & Pinch 1987
Pinch, T., Ashmore, M. and Mulkay, M. 1992. ‘Technology, testing, text: clinical budgeting in the UK National Health Service’, in W. Bijker and J. Law, (eds.), Shaping Technology/Building Society: Studies in Sociotechnical Change. Cambridge, MA: MIT Press, pp. 265–89
Pirmohamed, M. and Park, B. K. 2001. ‘Genetic susceptibility to adverse drug reactions’, Trends in Pharmacological Sciences 22(6): 298–305
Pirmohamed, M. and Park, B. K. 2003. ‘Adverse drug reactions: back to the future’, British Journal of Clinical Pharmacology 55(5): 486–92
Poirier, J. 1999a. ‘Apolipoprotein E: a pharmacogenetic target for the treatment of Alzheimer's disease’, Molecular Diagnosis 4(4): 335–41
Poirier, J. 1999b. ‘Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease’, Journal of Psychiatry and Neuroscience 24(2): 147–53
Poirier, J., Delisle, M. C., Quirion, R., Aubert, I., Farlow, M., Lahiri, D., Hui, S., Bertrand, P., Nalbantoglu, J., Gilfix, B. M. and Gauthier, S. 1995. ‘Apolipoprotein E allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease’, Proceedings of the National Academy of Sciences 92: 12260–4
Pollack, A. 1999. ‘In the works: drugs tailored to individual patients’, New York Times, 20 December, Section C, p. 8
Pollack, A. 2000. ‘Talking biotechnology with: George Rathmann’, New York Times, 18 December, Section C, p. 3
Pollack, A. 2002. ‘New era of consumer genetics raises hope and concerns’, New York Times, 1 October, Section F, p. 5
Post, S. G. 1996. ‘On not jumping the gun: ethical aspects of APOE gene testing for Alzheimer's disease’, in (N. R. Relkin, Z. Khachaturian and S. Gandy, (eds.), Apolipoprotein E Genotyping in Alzheimer's Disease: Annals of the New York Academy of Sciences. vol. 802. New York: New York Academy of Science
Post, S. G., Whitehouse, P. J., Binstock, R. H., Bird, T. D., Eckert, S. K., Farrer, L. A., Fleck, L. M., Gaines, A. D., Jeungst, E. T., Karlinsky, H., Miles, S., Murray, T. D., Quaid, K. A., Relkin, N. R., Roses, A. D., Georgehyslop, P. H. S., Sachs, G. A., Steinbock, B., Truschke, E. F. and Zinn, A. B. 1997. ‘The clinical introduction of genetic testing for alzheimer disease – an ethical perspective’, Journal of the American Medical Association 277(10): 832–6
Pricewaterhouse, Coopers 1998. Pharma 2005: An Industrial Revolution in R&D, http://www.pwcglobal.com/gx/eng/about/ind/pharma/industrial_revolution.pdf
Qizilibash, N., Whitehead, A., Higgins, J., Wilcock, G., Schneider, L. and Farlow, M. 1998. ‘Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the Tacrine trials’, Journal of the American Medical Association 280(20): 1777–82
Radford, T. 2003. ‘On the edge of a genetic revolution to map out medical future at birth’, Guardian, 25 June, p. 3
Rampaul, R. S., Pinder, S. E., Gullick, W. J., Robertson, J. F. R. and Ellis, I. O. 2002. ‘HER-2 in breast cancer – methods of detection, clinical significance and future prospects for treatment’, Critical Reviews in Oncology/Hematology 43: 231–44
Rapp, R. 2000. Testing Women, Testing the Fetus: The Social Impact of Amniocentesis in America. New York: Routledge
Raskind, M. A., Peskind, E. R., Wessel, T. and Yuan, W. 2000. ‘Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension’, Neurology 54: 2261–8
Regalado, A. 1999. ‘Inventing the pharmacogenomics business’, American Journal of Health-System Pharmacy 56: 40–50
Reichert, J. M. 2001. ‘Monoclonal antibodies in the clinic’, Nature Biotechnology 19: 819–22
Reichert, J. M. 2003. ‘Trends in development and approval times for new therapeutics in the United States’, Nature Reviews Drug Discovery 2: 695–702
Relkin, N. R., Kwon, Y. J., Tsai, J. and Gandy, S. 1996a. ‘Consensus statement: apolipoprotein E genotyping in Alzheimer's disease’, Lancet 347: 1091–5
Relkin, N. R., Kwon, Y. J., Tsai, J. and Gandy, S. 1996b. ‘The National Institute on Aging/Alzheimer's Association recommendations on the application of apolipoprotein E genotyping to Alzheimer's disease’, Annals of the New York Academy of Sciences 802: 149–71
Relman, A. S. and Angell, M. 2002. ‘America's other drug problem: how the drug industry distorts medicine and politics’, New Republic, 16 December: 27–41
Rennie, D. 1981. ‘Consensus statements’, New England Journal of Medicine 304(11): 665–6
Richard, F., Helbecque, N., Neuman, E., Guez, D., Levy, R. and Amouyel, P. 1997. ‘APOE genotyping and response to drug treatment in Alzheimer's disease’, Lancet 349: 539
Richard, F. and Amouyel, P. 2001. ‘Genetic susceptibility factors for Alzheimer's disease’, European Journal of Pharmacology 412: 1–12
Riekkinen, P. J., Koivisto, K. and Reinikaianen, (K. J. et al. 1998. ‘Can apo-4 subtype predict response to selegiline treatment in Alzheimer's disease?’, in E. Giacobini, A. Nordberg, J-P. Michel, B. Winblad and R. Becker (eds.), Proceedings of the 5th International Geneva/Springfield Symposium on Advances in Alzheimer's Therapy. Springfields, IL: Southern Illinois University Press, p. 91
Rigaud, A. S., Traykov, L., Caputo, L., Guelfi, M. C., Latour, F., Couderc, R., Moulin, F., Rotrou, J., Forette, F. and Boller, F. 2000. ‘The apolipoprotein E ∊4 allele and the response to tacrine therapy in Alzheimer's disease’, European Journal of Neurology 7: 255–8
Rioux, P. 2000. ‘Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications’, American Journal of Health System Pharmacy 57(9): 887–98
Ritchie, K. and Lovestone, S. 2002. The dementias, Lancet 360(9347): 1759–66
Roberts, F. D. 1999. Talking about Treatment: Recommendations for Breast Cancer Adjuvant Therapy. Oxford: Oxford University Press
Roberts, J. S. 2000. ‘Anticipating response to predictive testing for Alzheimer's disease: a survey of first-degree relatives’, Gerontologist 40(1): 43–52
Robertson, J. 2001. ‘Consent and privacy in pharmacogenetic testing’, Nature Genetics 28(3): 207–9
Robertson, J. A., Brody, B., Buchanan, A., Kahn, J. and McPherson, E. 2002. ‘Pharmacogenetic challenges for the health care system’, Health Affairs 21(4): 155–67
Roche, 2003. ‘Roche Diagnostics launches the AmpliChip’, press release, 25 June
Roden, D. M. and George, A. L. 2002. ‘The genetic basis of variability in drug responses’, Nature Reviews Drug Discovery 1: 37–44
Rodwin, M. A. 2001. ‘The politics of evidence-based medicine’, Journal of Health Politics, Policy and Law 26(2): 439–46
Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group 1998. ‘Consensus report of the Working Group on: “Molecular and Biochemical Maters of Alzheimer's Disease”’, Neurobiology of Aging 19(2): 109–16
Rose, S. 2003. ‘Science, not fiction’, Guardian, 15 November, Review section, p. 11
Roses, A. D. 1994. ‘Apolipoprotein affects the rate of Alzheimer's disease expression: ß-Amyloid burden is a secondary consequence dependent on APOE genotype and duration on disease’, Journal of Neuropathology and Experimental Neurology 53(5): 429–37
Roses, A. D. 1995a. ‘Apolipoprotein E genotyping in the differential diagnosis, not prediction of Alzheimer's disease’, Annals of Neurology 38(1): 6–14
Roses, A. D. 1995b. ‘Reply’, Annals of Neurology 38(6): 969
Roses, A. D. 1996a. ‘Apolipoprotein E alleles as risk factors in Alzheimer's disease’, Annual Review of Medicine 47: 387–400
Roses, A. D. 1996b. ‘Apolipoprotein E and Alzheimer's disease: a rapidly expanding field with medical and epidemiological consequences’, in (N. R. Relkin, Z. Khachaturian and S. Gandy (eds.), Apolipoprotein E Genotyping in Alzheimer's Disease: Annals of the New York Academy of Sciences, vol. 802: 50–7. New York: New York Academy of Sciences
Roses, A. D. 1996c. ‘Apolipoprotein E genotype: utility in clinical practice in Alzheimer's disease’, Journal of the American Geriatric Society 44: 1479–81
Roses, A. D. 1997a. ‘APOE4 genotyping: in reply’, Journal of the American Geriatric Society 45(9): 1155–6
Roses, A. D. 1997b. ‘Genetic testing for Alzheimer disease: practical and ethical issues’, Archives of Neurology 54: 1226–9
Roses, A. D. 1997c. ‘Letter: Various views on anonymity’, Nature Medicine 3(1): 2
Roses, A. D. 1998a. ‘A new paradigm for clinical evaluations of dementia: Alzheimer disease and apolipoprotein E genotypes’, in S. Post and P. Whitehouse (eds.), Genetic Testing for Alzheimer Disease: Ethical and Clinical Issues. Baltimore: Johns Hopkins University Press, pp. 37–64
Roses, A. D. 1998b. ‘Letter: Patent income’, Science 281, 18 September: 1805
Roses, A. D. 2000a. ‘Pharmacogenetics and future drug development and delivery’, Lancet 355: 1358–61
Roses, A. D. 2000b. ‘Pharmacogenetics and the practice of medicine’, Nature 405: 857–65
Roses, A. D. 2002a. ‘Genome-based pharmacogenetics and the pharmaceutical industry’, Nature Reviews Drug Discovery 1: 541–9
Roses, A. D. 2002b. ‘Pharmacogenetics’ place in modern medical science and practice', Life sciences 70: 1471–80
Roses, A. D. 2002c. ‘SNPs – where's the beef?’, Pharmacogenomics Journal 2: 277–83
Roses, A. D. and Saunders, A. M. 1996. ‘Letter: evaluation of suspected dementia’, New England Journal of Medicine 335(26): 1996
Roses, A. D. and Saunders, A. M. 1997. ‘Prediction for unimpaired subjects is different from diagnosis of demented patients’, Annals of Neurology 41(3): 414–15
Roses, A. D., Strittmatter, W., Periack-Vance, M. A., Corder, E. H., Saunders, A. M. and Schmechel, D. E. 1994. ‘Letter: clinical application of apolipoprotein E genotyping to Alzheimer's disease’, Lancet, 343: 1564–5
Ross, J. S. and Fletcher, J. A. 1998. ‘The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy’, Stem Cells 16: 413–28
Rothenberg, M. L., Cabone, D. P. and Johnson, D. H. 2003. ‘Improving the evaluation of new cancer treatments: challenges and opportunities’, Nature Reviews Cancer 3: 303–9
Rothman, B. K. 1998. Genetic Maps and Human Imaginations: The Limits of Science in Understanding Who We Are. New York: (W. W. Norton
Rothstein, M. A. (ed.) 2003. Pharmacogenomics: Social, Ethical and Clinical Dimensions. New York: John Wiley
Rothstein, M. and Griffin Epps, P. 2001. ‘Ethical and legal implications of pharmacogenomics’, Nature Reviews Genetics 2: 228–31
Rothstein, M. and Hornung, C. A. 2003. ‘Public attitudes about pharmacogenomics’, in Rothstein 2003
Rusnak, J. M., Kisabeth, R. M., Herbert, D. P. and McNeil, D. M. 2001. ‘Pharmacogenomics: a clinician's primer on emerging technologies for improved patient care’, Mayo Clinic Proceedings 76: 299–309
Sadée, W. 1999. ‘Pharmacogenomics’, British Medical Journal 319: 1286
Sainio, C. and Lauri, S. 2003. ‘Cancer patients’ decision-making regarding treatment and nursing care', Journal of Advanced Nursing 41(3): 250–60
Salter, B. G. 1998. The Politics of Change in the Health Service. London: Macmillan
Saunders, A. M., Strittmatter, W. J., Schmechel, D., Georgehyslop, P. H. S., Periack-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crappermaclachlan, D. R., Alberts, M. J., Hulette, C., Crain, B., Goldgaber, D. and Roses, A. D. 1993. ‘Association of apolipoprotein E allele ∊4 with late-onset familial and sporadic Alzheimer's disease’, Neurology 43: 1467–72
Saunders, A. M., Trowers, M. K., Shimkets, R. A., Blakemore, S., Crowther, D. J., Mansfield, T. A., Wallace, D. M., Strittmatter, W. J. and Roses, A. D. 2000. ‘The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection’, Biochimica et Biophysica Acta 1502: 85–94
Saunders, A. M., Hulette, C., Welsh-Bohmer, K. A., Schmechel, D. E., Crain, B., Burke, J. R., Alberts, M. J., Strittmatter, W. J., Breitner, J. C. S., Rosenberg, C., Scott, S. V., Gaskell, P. C., Periack-Vance, M. A. and Roses, A. D. 1996. ‘Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease’, Lancet 348: 90–3
Schappert, K., Sevigny, P. and Poirier, J. 2002. ‘Apolipoprotein E as a marker in the treatment of Alzheimer's disease’, in B. Lerer, (ed.), Pharmacogenetics of Psychotropic Drugs. Cambridge: Cambridge University Press, pp. 360–71
Schmitz, G., Aslanidis, C. and Lackner, K. J. 2001.‘Pharmacogenomics: implications for laboratory medicine’, Clinica Chimica Acta 308: 43–53
Schnitt, S. J. and Jacobs, T. W. 2001. ‘Current status of HER2 testing: caught between a rock and a hard place’, American Journal of Clinical Pathology 116: 806–10
Shak, S. 1999. ‘Overview of the Trastuzumab (Herceptin) Anti-HER2 Monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer’, Seminars in Oncology 26(4), supplement 12: 71–7
Shapiro, S. D. 2003. ‘The post-genomic red journal charting the path from hope (not hype) to cure’, American Journal of Respiratory Cell and Molecular Biology 29(4): 425–6
Shi, M. M., Bleavins, M. R. and Iglesia, F. 2001. ‘Pharmacogenetics application in drug development and clinical trials’, Drug Metabolism and Disposition 29(4), part 2: 591–5
Siest, G., Bertrand, P., Herbeth, B., Vincent-Viry, M., Schiele, F., Sass, C. and Visvikis, S. 2000. ‘Apolipoprotein E polymorphisms and concentration in chronic disease and drug responses’, Clinical Chemistry and Laboratory Medicine 38(9): 841–52
Sinding, C. 1996. ‘Literary genres and the construction of knowledge in biology: semantic shifts and scientific change’, Social Studies of Science 26: 43–70
Sjögren, M., Hesse, C., Basun, H., Köl, G., Thostrup, H., Kilander, L., Marcusson, J., Edman, A., Wallin, A., Karlsson, I., Troell, M., Wachtmaister, G., Ekdahl, A., Olofsson, H., Sandström, A., Andreasen, N., Minthon, L. and Blennow, K. 2001. ‘Tacrine and rate of progression in Alzheimer's disease – relation to ApoE allele genotype’, Journal of Neural Transmission 108: 451–8
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, A., Ullrich, A. and Press, M. F. 1987. ‘Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu Oncogene’, Science 235: 177–82
Smith, R. 2000. ‘The failings of NICE’, British Medical Journal 321: 1363–4
Spear, B. B., Heath-Chiozzi, M. and Huff, J. 2001. ‘Clinical applications of pharmacogenetics’, Trends in Molecular Medicine 7(5): 201–4
Speyer, J. 2002. ‘Cardiac dysfunction in the Trastuzumab clinical experience’, Journal of Clinical Oncology 20(5): 1156–7
Stebbing, J., Copson, E. and O'Reilly, S. (2000) ‘Herceptin (Trastuzumab) in advanced breast cancer’, Cancer Treatment Reviews 26: 287–90
Steimer, W. and Potter, J. M. 2002. ‘Pharmacogenetic screening and therapeutic drugs’, Clinica Chimica Acta 315: 137–55
Sugarman, J., McCrory, D. C., Powell, D., Krasny, A., Adams, B., Ball, E. and Cassell, C. 1999. ‘Empirical research on informed consent. An annotated bibliography’, Hastings Center Report 29(1): S1–42
Summers, W. K., Majovski, L. V., Marsh, G. M., Tachiki, K. and Kling, A. 1986. ‘Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type’, New England Journal of Medicine 315(20): 1241–45
Sun, . 2002. ‘Sun Says; Leading Article’, Sun. 16 March, p. 8
Sykes, R. 1999. ‘Medical innovation and imperatives’, Getting Better: Developing Mechanisms to Ensure the Best Benefit for Patients from Medical Progress, proceedings of conference, Brussels, 24 November, pp. 11–14
Taylor, K. M. 1992. ‘Integrating conflicting professional roles: physician participation in randomised clinical trials’, Social Science and Medicine 35(2): 217–24
Taylor, P. 1996. ‘Anticholinesterase agents’, in Goodman, and Gilman's The Pharmacological Basis of Therapeutics, ed. J. G. Hardman and L. E. Limbird. 9th edn. New York: McGraw-Hill, pp. 161–76
Thomas, F. and de Ribains, G. 1998. Pharmacogenomics. London: Financial Times
Thomas, S. 2001. ‘Pharmacogenetics: the ethical context’, Pharmacogenomics Journal 1: 239–42
Thornton, J. 2002. ‘Let this be last scandal’, Sun, 16 March, p. 29
Timmermans, S. and Berg, M. 2003. ‘The practice of medical technology’, Sociology of Health and Illness 25: 97–114
Tiner, T. 2003. ‘ABPI call for NICE guidance to be made mandatory’, Lancet Oncology 4: 203–4
Tollman, P., Guy, P., Altshuler, J., Flanagan, A. and Steiner, M. 2001. A Revolution in R&D. How Genomics and Genetics are Transforming the Biopharmaceutical Industry. Boston: Boston Consulting Group, http://www.bcg.com/publications/files/eng_genomicsgenetics_rep_11_01.pdf
Tozer, J. 2001. ‘Postcode lottery has condemned me to death; Despair of the cancer victims hit by drug “rationing”’, Daily Mail, 15 August, p. 32
Trojanowski, J. Q. 2002. ‘Tauists, Baptists, Syners, Apostates, and new data’, Annals of Neurology 52(3): 263–4
Tsai, Y. J. and Hoyme, H. E. 2002. ‘Pharmacogenomics: the future of drug therapy’, Clinical Genetics 62: 257–64
Tunstall, N. and Lovestone, S. 1999. ‘Letter: UK Alzheimer's Disease Genetics Consortium’, International Journal of Geriatric Psychiatry 14: 789–91
Turney, J. 1998. ‘Signs of life – taking genetic literacy seriously’, in P. Glasner and H. Rothman (eds), Genetic Imaginations – Ethical, Legal and Social Issues in Human Genome Research. Aldershot: Ashgate, p. 131–40
Gool, W. A. 1996. ‘The use of apolipoprotein E genotyping as a diagnostic test in suspected Alzheimer's disease’, Annals of the New York Academy of Sciences 802: 79–91
Lente, H. and Rip, A. 1998. ‘The rise of membrane technology: from rhetorics to social reality’, Social Studies of Science 28(2): 221–54
Varekamp, I., Krol, L. J. and Danse, J. A. C. 1998. ‘Age rationing for renal transplantation? The role of age in decisions regarding scarce life extending medical resources’, Social Science and Medicine 47(1): 113–20
Vaszar, L. T., Cho, M. K. and Raffin, T. A. 2003. ‘Privacy issues in personalized medicine’, Pharmacogenomics 4(2): 107–12
Vaszar, L. T., Rosen, G. D. and Raffin, T. A. 2002. ‘Pharmacogenomics and the challenge to privacy’, Pharmacogenomics Journal 2: 144–7
Veenstra, D. L. and Higashi, M. K. 2000. ‘Assessing the cost-effectiveness of pharmacogenomics’, AAPS Pharmsci 2(3), article 29: 1–11
Venter, C. 2000. ‘Genomic impact on pharmaceutical development’, in From Genome to Therapy: Integrating Technologies with Drug Development, Novartis Foundation Symposium 229. Chichester: John Wiley, pp. 14–18
Vesell, E. 2000. ‘Introduction’, Pharmacology 61: 118–23
Wachbroit, R. 1998. ‘The question not asked: the challenge of pleiotropic genetic tests’, Kennedy Institute of Ethics Journal 8(2): 131–44
Waitzkin, H. 1991. The Politics of Medical Encounters: how Patients and Doctors Deal with Social Problems. New Haven: Yale University Press
Walker, R. 2001. ‘Letter: “Spinning” is not nice’, British Medical Journal 322: 490
Warren, V. 1999. Genetic Tests and Future Need for Long-Term Care in the UK. http://www.phgu.org.uk/info_database/policy/cccreport.html
Watkins, P. B., Zimmerman, H. J., Knapp, M. J., Gracon, S. I. and Lewis, K. W. 1994. ‘Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease’, Journal of the American Medical Association 271: 992–8
Weber, W. W. 2001. ‘The legacy of pharmacogenetics and potential applications’, Mutation Research 479: 1–18
Wedlund, P. J. and Leon, J. 2001. ‘Pharmacogenomic testing: the cost factor’, Pharmacogenomics Journal 1: 171–4
Weinshilboum, R. 2002. ‘The genomic revolution and medicine’, Mayo Clinic Proceedings 77(8): 745–6
Weiss, R. 2000. ‘The promise of precision prescriptions; ‘pharmacogenomics’ also raises issues of race, privacy’, Washington Post, 24 June, p. A01
Welsh-Bohmer, K. A., Gearing, M., Saunders, A. M., Roses, A. D. and Mirra, S. 1997. ‘Apolipoprotein E genotypes in a neuropathological series from the consortium to establish a registry for Alzheimer's disease’, Annals of Neurology 42(3): 319–25
Whitehouse, P. J. 1998. ‘Therapeutic interventions in Alzheimer's disease: implications of genetic advances’, in (S. G. Post and (P. J. Whitehouse (eds.), Genetic Testing for Alzheimer's Disease: Ethical and Clinical Issues. Baltimore: Johns Hopkins University Press, pp. 65–82
Whitehouse, P. J. and Geldmacher, D. S. 1996. ‘Reply’, New England Journal of Medicine 335(26): 1997–8
Wieczorek, S. J. and Tsongalis, G. J. 2001. ‘Pharmacogenomics: will it change the field of medicine?’, Clinica Chimica Acta 308: 1–8
Wilcock, G. K., Lilienfeld, S. and Gaens, E. on behalf of the Galantamine International-1 Study Group. 2000. ‘Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial’, British Medical Journal, 9 December, 321: 1–7
Wilcock, G. K., MacGowan, S. H., Scott, M. and Dawbarn, D. 1995. ‘Apolipoprotein E genotype and response to tacrine in Alzheimer's disease’, poster presented at the International Psychogeriatrics Association Conference, Apolipoprotein E et Maladie d'Alzheimer, 29 May, Paris
Wiley, S. R. 1998. ‘Genomics in the real world’, Current Pharmaceutical Design 4: 417–22
Williams, C. J. and Buchanan, R. B. 1987. The Medical Management of Breast Cancer. Tunbridge Wells: Castle House
Winblad, B., Engedal, K., Soininen, H., Verhey, F., Waldemar, G., Wimo, A., Wetterholm, A. L., Zhang, R., Haglund, A. and Subbiah, P. 2001. ‘A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD’, Neurology 57: 489–95
Wiseman, H. 1994. Tamoxifen: Molecular Basis of Use in Cancer Treatment and Prevention. Chichester: John Wiley
Wolf, C. R., Smith, G. and Smith, R. L. 2000. ‘Pharmacogenetics’, British Medical Journal 320: 987–90
Woodman, R. 2000. ‘Storage of human organs prompts three inquiries’, British Medical Journal 320 (8 January): 77
Workman, P. 2001a. ‘Changing times: developing cancer in genomeland’, Current Opinion in Investigational drugs 2(8): 1128–35
Workman, P. 2001b. ‘Scoring a bull's-eye against cancer genome targets’, Current Opinion in Pharmacology 1: 342–52
World Medical Association 2000. Declaration of Helsinki. Geneva: World Medical Association
Yaziji, H. and Gown, A. M. 2002. ‘Testing for HER-2/neu in breast cancer: is fluorescence in situ hyridization superior in predicting outcome?’, Advances in Anatomic Pathology 9(6): 338–44
Young, R. and Surrusco, M. 2001. Rx R&D Myths: the Case Against the Drug Industry's R&D ‘Scare Card’. Washington, DC: Public Citizen Congress Watch
Yu, D. and Hung, M. 2000. ‘Role of erbB2 in breast cancer chemosensitivity’, BioEssays 22: 673–80
Zussman, R. 1992. Intensive Care: Medical Ethics and the Medical Profession. Chicago: University of Chicago Press
Zussman, R. 1997. ‘Sociological perspectives on medical ethics and decision-making’, Annual Review of Sociology 23: 171–89
